ArticleHaematologica2025

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Viktoriya Zelikson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.